

02-40000-10

[Original Effective Date: 10/15/99](#)

[Reviewed: 08/24/17](#)

[Revised: 07/19/18](#)

Subject: Bariatric Surgery

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

[Position Statement](#)

[Billing/Coding](#)

[Reimbursement](#)

[Program Exceptions](#)

[Definitions](#)

[Related Guidelines](#)

[Other](#)

[References](#)

[Updates](#)

DESCRIPTION:

Morbid obesity is defined as a body mass index (BMI) greater than 40 kg/m², or a BMI greater than 35 kg/m² with associated complications including, but not limited to, diabetes, hypertension, or obstructive sleep apnea. The first line of treatment of morbid obesity is dietary and lifestyle changes. When conservative measures fail, some individuals may consider surgical approaches. Surgery for morbid obesity, termed bariatric surgery, is performed for the treatment of morbid (clinically severe) obesity.

The evidence for bariatric surgery in individuals younger than age 18 years consists primarily of studies of adolescents, with a lack of evidence for younger children. There is limited evidence on which to assess the long-term impacts of bariatric surgery for adolescents. Very severely obese (BMI $\geq$ 40 kg/m²) adolescents with serious obesity-related comorbidities that are poorly controlled, and adolescents who have a BMI of $\geq$ 50 kg/m² with less serious comorbidities may be considered for bariatric surgery. There is greater emphasis on issues of developmental and [skeletal maturity](#) in adolescents.

The choice of procedure in adolescents may differ from adults, but there is a lack of consensus as to the preferred procedure(s) for adolescents. As in adults, laparoscopic gastric bypass is the most common procedure in adolescents. Devices that are used for laparoscopic adjustable gastric banding do not have FDA-approval in the U.S. for individuals younger than age 18 years.

Bariatric surgery procedures may be restrictive procedures, malabsorptive procedures, or a combination of the two. The different types of bariatric surgery procedures are described below.

Open and laparoscopic Roux-en-Y Gastric Bypass (RYGB) (up to 150 cm)

The gastric bypass procedure involves both a restrictive and a malabsorptive component, with horizontal or vertical partition of the stomach performed in association with a Roux-en-Y procedure (i.e., a gastrojejunal anastomosis). The flow of food bypasses the duodenum and proximal small bowel. The procedure may also be associated with an unpleasant “dumping syndrome,” in which a large osmotic load delivered directly to the jejunum from the stomach produces abdominal pain and/or vomiting. The dumping syndrome may further reduce intake, particularly in “sweets eaters.” Operative complications include leakage and marginal ulceration at the anastomotic site. Because the normal flow of food is disrupted, there are more metabolic complications compared to other gastric restrictive procedures, including iron deficiency anemia, vitamin B-12 deficiency, and hypocalcemia, all of which can be corrected by oral supplementation. Another concern is the ability to evaluate the “blind” bypassed portion of the stomach. Gastric bypass may be performed with either an open or laparoscopic technique.

Laparoscopic Adjustable [Gastric Banding](#) (LAGB) (eg, LapBand®, Realize®)

Adjustable gastric banding involves placing a gastric band around the exterior of the stomach. The band is attached to a reservoir that is implanted subcutaneously in the rectus sheath. Injecting the reservoir with saline will alter the diameter of the gastric band; therefore, the rate-limiting stoma in the stomach can be progressively narrowed to induce greater weight loss, or expanded if complications develop. Because the stomach is not entered, the surgery and any revisions, if necessary, are relatively simple. Complications include slippage of the external band or band erosion through the gastric wall.

Biliopancreatic Bypass with Duodenal Switch (BPD/DS)

The duodenal switch procedure is essentially a variant of the biliopancreatic bypass. In this procedure, instead of performing a distal gastrectomy, a sleeve gastrectomy is performed along the vertical axis of the stomach. This approach preserves the pylorus and initial segment of the duodenum, which is then anastomosed to a segment of the ileum, similar to the biliopancreatic bypass, to create the alimentary limb. Preservation of the pyloric sphincter is intended to ameliorate the dumping syndrome and decrease the incidence of ulcers at the duodenoileal anastomosis by providing a more physiologic transfer of stomach contents to the duodenum. The sleeve gastrectomy also decreases the volume of the stomach and decreases the parietal cell mass. However, the basic principle of the procedure is similar to that of the biliopancreatic bypass, i.e., producing selective malabsorption by limiting the food digestion and absorption to a short, common ileal segment.

Sleeve gastrectomy (SG)

A sleeve gastrectomy is an alternative approach to gastrectomy that can be performed on its own, or in combination with malabsorptive procedures (most commonly biliopancreatic diversion with duodenal switch). In this procedure, the greater curvature of the stomach is resected from the angle of His to the distal antrum, resulting in a stomach remnant shaped like a tube or sleeve. The pyloric sphincter is preserved, resulting in a more physiologic transit of food from the stomach to the duodenum, and avoiding the dumping syndrome (overly rapid transport of food through the stomach into the intestines).

that is seen with distal gastrectomy. This procedure can be performed by the open or laparoscopic technique. Some surgeons have proposed the sleeve gastrectomy as the first in a 2-stage procedure for very high-risk individuals.

Biliopancreatic Bypass Diversion (Scopinaro procedure)

A biliopancreatic bypass (BPD) procedure consists of a subtotal gastrectomy and diversion of the biliopancreatic juices into the distal ileum by a long Roux-en-Y procedure. BPD consists of the following components:

- A distal gastrectomy induces a temporary early satiety and/or the dumping syndrome in the early postoperative period, both of which limit food intake.
- A 200 cm long “alimentary tract”, consisting of 200 cm of ileum connecting the stomach to a common distal segment.
- A 300 to 400 cm “biliary tract” which connects the duodenum, jejunum, and remaining ileum to the common distal segment.
- A 50 to 100 cm “common tract,” where food from the alimentary tract mixes with biliopancreatic juices from the biliary tract. Food digestion and absorption, particularly of fats and starches, are therefore limited to this small segment of bowel, creating a selective malabsorption. The length of the common segment will influence the degree of malabsorption.
- Because of the high incidence of cholelithiasis associated with this procedure, cholecystectomy is usually performed.

Long-limb gastric bypass (> 150cm)

Recently, variations of gastric bypass procedures have been described, consisting primarily of long-limb Roux-en-Y procedures, which vary in the length of the alimentary and common limbs. For example, the stomach may be divided with a long segment of the jejunum (instead of ileum) anastomosed to the proximal gastric stump, creating the alimentary limb. The remaining pancreaticobiliary limb, consisting of stomach remnant, duodenum, and length of proximal jejunum, is then anastomosed to the ileum, creating a common limb of variable length in which the ingested food mixes with the pancreaticobiliary juices. While the long alimentary limb permits absorption of most nutrients, the short common limb primarily limits absorption of fats. The stomach may be bypassed in a variety of ways, i.e., either by resection or stapling along the horizontal or vertical axis. Unlike the traditional gastric bypass, which is essentially a gastric restrictive procedure, these very long-limb Roux-en-Y gastric bypasses combine gastric restriction with some element of malabsorptive procedure, depending on the location of the anastomoses.

Vertical Banded Gastroplasty (VBG)

In vertical banded gastroplasty, the stomach is segmented along its vertical axis. To create a durable reinforced and rate-limiting stoma at the distal end of the pouch, a plug of stomach is removed, and a propylene collar is placed through this hole and then stapled to itself. Because the normal flow of food is

preserved, metabolic complications are uncommon. Complications include esophageal reflux, dilation, or obstruction of the stoma, with the latter two requiring reoperation. Dilation of the stoma is a common reason for weight regain. Vertical banded gastroplasty may be performed using an open or laparoscopic approach.

Mini-Gastric Bypass

A variant of the gastric bypass, called the “mini-gastric bypass” has been popularized. Using a laparoscopic approach, the stomach is segmented, similar to a traditional gastric bypass, but instead of creating a Roux-en-Y anastomosis, the jejunum is anastomosed directly to the stomach, similar to a Billroth II procedure. This unique aspect of this procedure is not based on its laparoscopic approach, but rather the type of anastomosis used.

Endoluminal (also called endosurgical, endoscopic or natural orifice) bariatric procedures

With these procedures, access to the relevant anatomical structures is gained through the mouth without skin incisions. Primary and revision/conversion bariatric procedures are being developed to reduce the risks associated with open and laparoscopic interventions. Examples of endoluminal bariatric procedures studied include gastroplasty using a transoral endoscopically guided stapler, and placement of devices such as a duodenal-jejunal sleeve and gastric balloon. Endoluminal techniques for bariatric surgery include but may not be limited to the following:

- **Endoscopic duodenal-jejunal bypass:** A procedure that involves an endoscopically placed duodenal-jejunal bypass liner (EndoBarrier™) is utilized to promote weight loss by preventing food from coming in contact with the intestinal wall, and inhibiting the absorption of food and nutrients in individuals who are potential candidates for bariatric surgery.
- **Endoscopic gastroplasty:** This is an incision-less, reversible procedure in which the stomach size is restricted with staples or sutures by using endoscopic surgical tools guided through the mouth and esophagus into the stomach.
- **Endoscopic procedures** (e.g., insertion of the StomaphyX™ device, ROSE procedure; restorative obesity surgery) to treat weight gain after bariatric surgery to remedy large gastric stomas or large gastric pouches.

Laparoscopic Gastric Plication

Laparoscopic gastric plication is a bariatric surgery procedure that involves laparoscopic placement of sutures over the greater curvature (laparoscopic greater curvature plication) or anterior gastric region (laparoscopic anterior curvature plication) to create a tube-like stomach. The procedure involves 2 main steps, mobilization of the greater curvature of the stomach and suture plication of the stomach for achieving gastric restriction, but specifics of the technique are not standardized.

Single anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S)

Single anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S) is a bariatric surgery procedure that is based on the biliopancreatic diversion. A sleeve gastrectomy is performed and is then

followed by an end-to-side duodenoileal diversion. Preservation of the pylorus makes a one loop reconstruction possible. This is thought to reduce the time required for surgery, and eliminate the need for a mesentery opening.

Aspiration Therapy Device

Aspiration therapy involves an FDA-approved device (AspireAssist) that allows patients to drain a portion of the stomach contents after meals via an implanted tube connected to an external skin port. The total amount of data on aspiration therapy is very limited, and additional studies are needed before conclusions can be drawn about the long-term effects of treatment on weight loss, metabolism, and nutrition.

POSITION STATEMENT:

Certificate of Medical Necessity

Submit a completed Certificate of Medical Necessity (CMN) along with your request to expedite the medical review process.

1. Click the link Bariatric Surgery under Certificates of Medical Necessity in the side navigation of this page to access the form.
2. Complete all fields on the form thoroughly.
3. Print and submit a copy of the form with your request.

Note: Florida Blue regularly updates CMNs. Ensure you are using the most current copy of a CMN before submitting to Florida Blue.

Bariatric surgery may be excluded by contract. Please refer to the individual member contract benefit language.

When **selection criteria** are met, the following bariatric surgery procedures performed for the treatment of clinically severe (morbid) obesity **meet the definition of medical necessity**:

Open or laparoscopic Roux-en-Y gastric bypass (RYGB) (up to 150cm) (CPT codes 43846, 43644)

Laparoscopic adjustable gastric banding (LAGB) (FDA approved ≥ 18 years) (CPT code 43770)

Biliopancreatic bypass with duodenal switch (BPD/DS) (CPT code 43845)

Sleeve gastrectomy (SG) (CPT code 43775)

Biliopancreatic bypass diversion (Scopinaro) (CPT code 43847)

Vertical banded gastroplasty (CPT code 43842)

Selection criteria

Adults

Severely obese with a **BMI ≥ 40 kg/m²**, **OR**

Severely obese with a **BMI ≥ 35 kg/m²**, with at least one comorbidity refractory to medical management (e.g., type 2 diabetes, hypertension, coronary artery disease, obstructive sleep apnea, GERD, osteoarthritis, [pseudotumor cerebri](#)), **AND**

Does not have a medically treatable cause for obesity (e.g., thyroid or other endocrine disorder), **AND**

Has made multiple attempts at non-surgical weight loss (e.g., diet, exercise, medications), **AND**

Has received psychological or psychiatric evaluation with counseling as needed, prior to surgical intervention.

Adolescents (< age 18 years)

Severely obese with a **BMI ≥ 50 kg/m²**, with at least one less serious comorbidity refractory to medical management (e.g., hypertension, dyslipidemia, venous stasis disease, coronary artery disease, nonalcoholic fatty liver disease, GERD, osteoarthritis, recurrent soft tissue infections, significant impairment in activities of daily living), **OR**

Severely obese with a **BMI ≥ 40 kg/m²**, with at least one serious comorbidity refractory to medical management (e.g., obstructive sleep apnea, type 2 diabetes, pseudotumor cerebri), **AND**

Does not have a medically treatable cause for obesity (e.g., thyroid or other endocrine disorder), **AND**

Has attained a minimum of [Tanner stage](#) 4 pubertal development, **AND**

Has reached skeletal maturity, **AND**

Has made multiple attempts at non-surgical weight loss (e.g., diet, exercise, medications), **AND**

Has received psychological or psychiatric evaluation with counseling as needed, prior to surgical intervention.

Any bariatric surgical procedure for the treatment of obesity in individuals with a BMI < 35 kg/m² **does not meet the definition of medical necessity.**

The bariatric surgery procedures listed below are considered **experimental or investigational**, as there is insufficient clinical evidence in the peer-reviewed literature to support safety, effectiveness and long-term effects on health outcomes.

Long-limb gastric bypass (> 150cm) (CPT code 43847)

Laparoscopic gastric plication (also known as laparoscopic greater curvature plication)

Mini-gastric bypass (using a Billroth type anastomosis)

Insertion of the StomaphyX™ device

Endoscopic gastroplasty

Endoscopically placed duodenojejunal sleeve

Intragastric balloons

ROSE procedure

Restorative obesity surgery

Biliopancreatic bypass without duodenal switch (CPT code 43845)

Two-stage bariatric surgery procedures (e.g., sleeve gastrectomy as an initial procedure followed by biliopancreatic diversion at a later time)

Any bariatric surgical procedure as a treatment of type 2 diabetes in individuals with a BMI < 35 kg/m²

“Stomach stapling”, [jejunoileal bypass](#), silastic ring vertical gastric bypass (Fobi pouch; limiting proximal gastric pouch)

- Single anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S)

Aspiration therapy device

Any bariatric surgery procedure performed as the primary treatment for gastroparesis, intractable nausea, gallstones, urinary stress incontinence, gynecological abnormalities, osteoarthritis

Revision/conversion bariatric surgery

Revision/conversion bariatric surgery to address perioperative or late complications of a bariatric procedure (e.g., obstruction, stricture, erosion, band slippage/herniation, fistula, disruption/leakage of a suture/staple line, pouch enlargement due to vomiting, nonabsorption resulting in hypoglycemia or malnutrition, weight loss of 20% or more below ideal body weight) **meets the definition of medical necessity.**

Revision/conversion of a primary bariatric procedure that has failed due to dilation of the gastric pouch or dilation proximal to an adjustable gastric band **meets the definition of medical necessity** when **ALL** of the following are met:

The dilation is documented by upper gastrointestinal examination or endoscopy

The initial procedure induced weight loss prior to pouch dilation

The individual has been compliant with a prescribed nutrition and exercise program

Revision/conversion bariatric surgery to correct stretching of a stomach pouch created by a previous bariatric surgery procedure, due to overeating, is not considered a surgical complication.

Revision/conversion surgery for this condition **does not meet the definition of medical necessity**.

BILLING/CODING INFORMATION:

CPT Coding:

43633	Gastrectomy, partial, distal; with Roux-en-Y reconstruction
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (Roux limb 150 cm or less)
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption [NOTE: 43645 was introduced in 2005 to specifically describe a laparoscopic malabsorptive procedure. However, the code does not describe any specific malabsorptive procedure]
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g. gastric band and subcutaneous port components)
43771	Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only
43772	Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only
43773	Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only
43774	Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device and subcutaneous port components
43775	Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (i.e. sleeve gastrectomy)
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy (may be done laparoscopically)
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption (may be done laparoscopically)

43848	Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure)
43886	Gastric restrictive procedure, open; revision of subcutaneous port component only
43887	Gastric restrictive procedure, open; removal of subcutaneous port component only
43888	Gastric restrictive procedure, open; removal and replacement of subcutaneous port component only

NOTE: CPT code 43847 may be used to report biliopancreatic bypass (Scopinaro procedure) **OR** long-limb gastric bypass (> 150 cm). CPT code 43846 explicitly describes a short limb (< 150 cm) Roux-en-Y gastroenterostomy, and thus is not appropriate to report long-limb gastric bypass.

HCPCS Coding:

S2083	Adjustment of gastric band diameter via subcutaneous port by injection or aspiration of saline
-------	--

LOINC Codes:

The following information may be required documentation to support medical necessity: physician history and physical (including co-morbidities and history of attempt(s) of non-surgical weight-loss program(s), physician progress notes, laboratory studies (including most recent TSH level), psychosocial assessment, height, weight and BMI.

Documentation Table	LOINC Codes	LOINC Time Frame Modifier Code	LOINC Time Frame Modifier Codes Narrative
Physician history and physical	28626-0	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Attending physician progress notes	18741-9	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Laboratory studies	26436-6	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Psychosocial well-being,	58168-6	18805-2	Include all data of the selected type that represents observations made six months or fewer before

addressed in care plan			starting date of service for the claim.
Body mass index	39156-5	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Height and weight	54567-3	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Co-morbidities and complications	42126-3	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Endocrine screen assessment	39177-1	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.

REIMBURSEMENT INFORMATION:

Bariatric surgical procedures are reimbursed based on the procedure performed and not the surgical technique used (e.g., microsurgical, laser, laparoscopic, robot-assisted).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage:

The following National Coverage Determinations (NCDs) were reviewed on the last guideline reviewed date: Bariatric Surgery for Treatment of Morbid Obesity (100.1), Surgery for Diabetes (100.14), Gastric Balloon for Treatment of Obesity (100.11), and Intestinal Bypass Surgery (100.8) located at cms.gov.

The following Local Coverage Determination (LCD) was reviewed on the last guideline reviewed date: Surgical Management of Morbid Obesity (L33411) located at fcso.com.

DEFINITIONS:

Gastric banding: a synthetic band rather than staples is used to divide the stomach into a small upper pouch and a lower portion).

Jejunioleal bypass: shunts food from the jejunum into the ileum, bypassing the small intestine.

Pseudotumor cerebri: when elevated intracranial pressure occurs with no obvious cause; symptoms mimic those of a brain tumor, but no tumor is present.

Skeletal maturity: when the bones and spine have stopped growing; a system of fused skeletal bones, which occurs when bone growth ceases after puberty.

Tanner staging: also known as the sexual maturity rating; breaks down the visible changes during puberty into stages of sexual development.

RELATED GUIDELINES:

[Gastric Electrical Stimulation, 01-91000-04](#)

[Reconstructive Surgery/Cosmetic Surgery, 02-12000-01](#)

[Vagus Nerve Stimulation, 02-61000-22](#)

OTHER:

None applicable.

REFERENCES:

1. Abdelbaki TN, Huang CK, Ramos A, Neto MG, Talebpour M, Saber AA. Gastric plication for morbid obesity: a systematic review. *Obes Surg*. 2012 Oct;22(10):1633-9.
2. AHRQ National Guideline Clearinghouse. NGC-6413 SAGES Guideline for clinical application of laparoscopic bariatric surgery. 2003 Jul (revised 2008 Oct). (Accessed 09/27/13).
3. AHRQ National Guideline Clearinghouse. NGC-6609. Role of endoscopy in the bariatric surgery patient. *Gastrointest Endosc* 2008 Jul;68(1):1-10.
4. AHRQ National Guideline Clearinghouse. NGC-6638 Expert panel on weight loss surgery executive report. 2004 Aug 4 (revised 2007 Dec 12).
5. AHRQ National Guideline Clearinghouse. NGC-6716 American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic and nonsurgical support of the bariatric surgery patient. 2008 Jul-Aug.
6. AHRQ Comparative Effectiveness Review Number 82. Bariatric Surgery and Nonsurgical Therapy in Adults With Metabolic Conditions and a Body Mass Index of 30.0 to 34.9 kg/m². Prepared by: Southern California Evidence-based Practice Center. June 2013.
7. AHRQ National Guideline Clearinghouse. NGC-10217. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient - 2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery. *Endocr Pract*. 2013 Mar - Apr;19(2):337-72.
8. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical Guidelines for Clinical Practice for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient. *Surgery for Obesity and Related Diseases* 4 (2008) S109-S184.

9. American College of Gastroenterology. Clinical guideline: Management of Gastroparesis (2013). *Am J Gastroenterol.* 2013 Jan;108(1): 18-37.
10. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol.* 2013 Mar;108(3): 308-28.
11. American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE). Position Statement on the Prevention, Diagnosis and Treatment of Obesity (1998 Revision).
12. American Diabetes Association. Standards of Medical Care in Diabetes-2009. *Diabetes Care*, Vol 32 Supplement 1, January 2009. Accessed 03/05/09.
13. American Diabetes Association. Standards of Medical Care in Diabetes-2010. *Diabetes Care*, Vol 32 Supplement 1, January 2010.
14. American Diabetes Association. Standards of Medical Care in Diabetes-2011. *Diabetes Care*, Vol 34 Supplement 1, January 2011.
15. American Gastroenterological Association Medical Position Statement on Obesity. *Gastroenterology* 2002;123:879-881.
16. American Medical Association CPT Coding (current edition).
17. American Society for Bariatric Surgery (ASBS) and the Society of American Gastrointestinal Endoscopic Surgeons (SAGES). Guidelines for laparoscopic Bariatric Surgery. *SAGES*, 03/25/08 (Accessed 09/27/13).
18. American Society for Bariatric Surgery (ASBS) and the Society of American Gastrointestinal Endoscopic Surgeons (SAGES). Guidelines for laparoscopic and open surgical treatment of morbid obesity (ASBS/SAGES, 2000) (accessed 04/18/07).
19. American Society for Bariatric Surgery (ASBS). Position Statement on Sleeve Gastrectomy as a Bariatric Procedure. (*ASMBS* 06/17/07) (Accessed 03/20/08).
20. American Society for Metabolic & Bariatric Surgery. Position Statement on Preoperative Supervised Weight Loss Requirements. *Surgery for Obesity and Related Diseases* 7 (2011) 257–260.
21. American Society for Metabolic & Bariatric Surgery. Updated Position Statement on Sleeve Gastrectomy as a Bariatric Procedure, 10/28/11.
22. American Society for Metabolic and Bariatric Surgery Statements and Guidelines. Bariatric surgery in class I obesity (body mass index 30–35 kg/m²). *Surgery for Obesity and Related Diseases* 9 (2013) e1–e10.
23. American Society for Metabolic and Bariatric Surgery. Pediatric Best Practice Guidelines (January 2012). Accessed at <https://asmbs.org/resources/pediatric-best-practice-guidelines>.
24. American Society for Metabolic and Bariatric Surgery. ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy. White Paper: A pathway to endoscopic bariatric therapies. *Surgery for Obesity and Related Diseases* 7 (2011) 672–682.
25. American Society for Metabolic and Bariatric Surgery. Updated position statement on sleeve gastrectomy as a bariatric procedure. *Surg Obes Relat Dis.* May-Jun 2012; 8(3):e21-26.
26. American Society for Metabolic and Bariatric Surgery. Policy Statement on Gastric Plication (May 2011). Accessed at <https://asmbs.org/resources/policy-statement-on-gastric-plication>.
27. Andrade CG, Lobo A. Weight loss in the first month post-gastroplasty following diet progression with introduction of solid food three weeks after surgery. *Arq Bras Cir Dig.* 2014;27 Suppl 1:13-6.
28. Appel LJ et al. Comparative Effectiveness of Weight-Loss Interventions in Clinical Practice. *N Engl J Med* 2011;365:1959-68.

29. Arias E, Martínez PR, Ka Ming Li V, Szomstein S, Rosenthal RJ. Mid-term Follow-up after Sleeve Gastrectomy as a Final Approach for Morbid Obesity. *Obes Surg*. 2009 Mar 12.
30. August GP, Caprio S, Fennoy I et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. *J. Clin. Endocrinol. Metab*. 2008; 93(12):4576-99.
31. Bleich SN et al. Impact of Bariatric Surgery on Health Care Utilization and Costs Among Patients With Diabetes. *Medical Care* Volume 50, Number 1, January 2012.
32. Blue Cross Blue Shield Association Medical Policy 7.01.47. Bariatric Surgery. April 2017.
33. Blue Cross Blue Shield Association TEC Assessment; Laparoscopic adjustable gastric banding for morbid obesity (2006).
34. Blue Cross Blue Shield Association TEC Assessment; Laparoscopic gastric bypass surgery for morbid obesity (2005).
35. Blue Cross Blue Shield Association TEC Evaluation (12/88), 2003.
36. Blue Cross Blue Shield Association TEC Special Report: The relationship between weight loss and changes in morbidity following bariatric surgery for morbid obesity. BCBSA TEC Assessment Program, 2003; 18:1-25.
37. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC), TEC Assessment Program. Bariatric Surgery In Patients With Diabetes And Body Mass Index Less Than 35 kg/m² . October 2012; Volume 27, Tab E.
38. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC), TEC Assessment Program. Laparoscopic Adjustable Gastric Banding In Patients With Body Mass Index Less Than 35 kg/m² With Weight-Related Comorbidity. October 2012; Volume 27, Tab F.
39. Bolen SD, Chang HY, Weiner JP, Richards TM, Shore AD, Goodwin SM, Johns RA, Magnuson TH, Clark JM. Clinical outcomes after bariatric surgery: a five-year matched cohort analysis in seven US states. *Obesity Surgery* 22, no. 5 (2012): 749-763.
40. Bolton J, et al. Endoscopic Revision (StomaphyX) versus Formal Surgical Revision (Gastric Bypass) for Failed Vertical Band Gastroplasty. *Journal of Obesity* Volume 2013, Article ID 108507. Hindawi Publishing Corporation.
41. Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. *Surg Obes Relat Dis*. Feb 22 2014.
42. Caio EG, Reis J, Alvarez-Leite I, Bressan J, Alfenas RC. Role of Bariatric-Metabolic Surgery in the Treatment of Obese Type 2 Diabetes with Body Mass Index < 35kg/m²: A Literature Review. *Diabetes Technology & Therapeutics*. April 2012, 14(4): 365-372.
43. California Technology Assessment Forum (CTAF). Laparoscopic Adjustable Silicone Banding for Morbid Obesity, (02/28/07).
44. Canadian Agency for Drugs and Technologies in Health (CADTH). Laparoscopic Adjustable Banding for Weight Loss in Adults: Clinical and Economic Review. (09/07).
45. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for Bariatric Surgery for Treatment of Morbid Obesity, Publication 100-3, Section 100.1 (09/24/13).
46. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for Surgery for Diabetes, Publication 100-3, Section 100.14 (02/12/09).
47. Centers for Medicare and Medicaid Services (CMS) Decision Memo for Surgery for Diabetes (CAG-00397N); 02/02/09.
48. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Bariatric Surgery for the Treatment of Morbid Obesity (CAG-00250R2). 06/27/12.

49. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for Gastric Balloon, Publication 100-3, Section 100.11, 09/18/87.
50. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for Intestinal Bypass Surgery, Publication 100-3, Section 100.8.
51. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for Treatment of Obesity, Publication 100-3, Section 40.5, 02/21/06.
52. Chakhtoura G, Zinzindohoué F, Ghanem Y, Ruseykin I, Dutranoy JC, Chevallier JM. Primary results of laparoscopic mini-gastric bypass in a French obesity-surgery specialized university hospital. *Obes Surg.* 2008 Sep;18(9):1130-3.
53. Chiapaikao D, et al. Analysis of reoperations after laparoscopic adjustable gastric banding. *JSLs.* 2014 Oct-Dec;18(4). pii: e2014.00210.
54. Clarke MG, Wong K, Pearless L, Booth M. Laparoscopic Silastic Ring Mini-gastric Bypass: a Single Centre Experience. *Obesity Surgery* November 2013, Volume 23, Issue 11, pp 1852-1857.
55. ClinicalTrials.gov. NCT01685177: Single Anastomosis Duodeno-Ileal Bypass vs Standard Duodenal Switch as a Second Step After Sleeve Gastrectomy in the Super-Morbid Obese Patient (SADI vs CD). September 2012.
56. ClinicalTrials.gov. Advanced Medical Therapy vs. Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes. Identifier NCT00432809. Phase IV. Verified by The Cleveland Clinic. (11/07).
57. ClinicalTrials.gov. Effects Of Bariatric Surgery on Insulin. Identifier NCT00535600. Verified by National Institute of Health Clinical Center, (09//07).
58. ClinicalTrials.gov. Longitudinal Study of Bariatric Surgery. Identifier NCT00433810. Verified by National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). (12/07).
59. ClinicalTrials.gov. Teen-Longitudinal Assessment of Bariatric Surgery (Teens-LABS) Adolescent Bariatrics: Assessing Health benefits and Risk. Identifier NCT00474318. Verified by Children's Hospital Medical Center, Cinicinati. (05/07).
60. ClinicalTrials.gov. NCT02142257: Comparison of Gastric Bypass and AspireAssist Aspiration Therapy for Treatment of Morbid Obesity. Blekinge County Council Hospital (January 2016).
61. ClinicalTrials.gov. NCT01766037: Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study (PATHWAY). Boston Medical Center, Brigham and Women's Hospital, Cornell University, Howard University, and Mayo Clinic (January 2017).
62. Colquitt J, Clegg A, Loveman E, Royle P, Sidhu MK. Surgery for morbid obesity. *Cochrane Database of Systematic Reviews* 2005, Issue 4. Art. No.: CD003641. DOI: 10.1002/14651858.CD003641.pub2.
63. Coskun H, Cipe G, Bozkurt S, Bektasoglu HK, Hasbahceci M, Muslumanoglu M. Laparoscopic sleeve gastrectomy in management of weight regain after failed laparoscopic plication. *Int J Surg Case Rep.* 2013;4(10):872-4.
64. Dailey G. Early and Intensive Therapy for Management of Hyperglycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes. *Clinical Therapeutics/Volume 33, Number 6,* 2011.
65. de Jonge C, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, le Roux CW, Schaper NC, Bouvy ND, Greve JW. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. *Obes Surg.* 2013 Sep;23(9):1354-60.
66. DeMaria, E J, Sugerman, H J, Meador, J G, et al. High Failure Rate After Laparoscopic Adjustable Silicone Gastric Banding for Treatment of Morbid Obesity. *Annals of Surgery* 2001:233:809-818.

67. Dang H, Arias E, Szomstein S, Rosenthal R. (2009). Laparoscopic conversion of distal mini-gastric bypass to proximal Roux-en-Y gastric bypass for malnutrition: case report and review of the literature. *Surgery for Obesity and Related Diseases*, 5(3), 383-386.
68. Darabi S, Talebpour M, Zeinoddini A, Heidari R. Laparoscopic gastric plication versus mini-gastric bypass surgery in the treatment of morbid obesity: a randomized clinical trial. *Surg Obes Relat Dis*. 2013 Nov-Dec;9(6):914-9.
69. Dixon JB, Obrien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M. Adjustable Gastric Banding and Conventional Therapy for Type 2 Diabetes. A Randomized Controlled Trial. *JAMA* 2008;299 (3): 316-323.
70. Dolan K, Hatzifotis M, Newbury L et al. A clinical and nutritional comparison of biliopancreatic diversion with and without duodenal switch. *Ann. Surg.* 2004; 240(1):51-6.
71. Dorman RB, Rasmus NF, al-Haddad BJS, Serrot FJ, Slusarek BM, Sampson BK, Buchwald H, Leslie DB, Ikramuddin S. Benefits and complications of the duodenal switch/biliopancreatic diversion compared to the Roux-en-Y gastric bypass. *Surgery* (2012).
72. Duarte MI, et al. Impact on quality of life, weight loss and comorbidities: a study comparing the biliopancreatic diversion with duodenal switch and the banded Roux-en-Y gastric bypass. *Arq Gastroenterol*. 2014 Oct-Dec;51(4):320-7.
73. ECRI Institute. Comprehensive Technology Assessment. Bariatric Surgery for Obesity (2007), (accessed 04/17/07).
74. ECRI Institute. Hotline Custom Reponse. Safety and Efficacy of StomaphyX Device for Gastric Pouch Reduction after Gastric Bypass Surgery. (Updated 02/11/08) (Accessed 03/10/08).
75. ECRI Institute. Hotline Custom Resonse. Laparoscopic Sleeve Gastrectomy (LSG) for Morbid Obesity. (Updated 01/22/07) (Accessed 03/10/08).
76. ECRI Institute. Hotline Custom Response. Adjustable Gastric Banding for Morbid Obesity (Updated 01/12/07) 9. Accessed 03/10/08).
77. ECRI Institute. Windows on Medical Technology. Laparoscopic Bariatric Surgery for Morbid Obesity, Issue 126, (05/02).
78. ECRI Institute Emerging Technology Evidence Report. Metabolic Surgery for Resolving Type 2 Diabetes Mellitus in Patients with BMI <35 kg/m². July 2013.
79. ECRI Institute Health Technology Forecast. Metabolic (Bariatric) Surgery for Treating Type 2 Diabetes Mellitus in Patients with BMI <35 kg/m². April 2013.
80. ECRI Institute Health Technology Forecast. Endoluminal Sleeve (EndoBarrier) for Preoperative Weight Loss or Treating Obesity. April 2013.
81. Emerging Technologies and Clinical Issues Committees of the ASMBS. American Society for Metabolic and Bariatric Surgery Position Statement on emerging endosurgical interventions for treatment of obesity. *Surg Obes Rel Dis* 2009; 5(3):297-8. Available online at: http://www.asmb.org/Newsite07/resources/emerging_tech_position.pdf. (Accessed 06/25/12)
82. Evidence Report/Technology Assessment: Bariatric Surgery in Women of Reproductive Age: Special Concerns for Pregnancy. AHRQ Publication No. 08-E013, prepared by the Southern California Evidence-based Practice Center. Santa Monica, Ca. November 2008.
83. Evidence Report/Technology Assessment: Effectiveness of Weight management Programs In Children and Adolescents. AHRQ Publication No. 08-E014, prepared by the Oregon Evidence-based Practice Center, Portland OR. September 2008.
84. Finkelstein EA et al. Financial implications of coverage for laparoscopic adjustable gastric banding. *Surgery for Obesity and Related Diseases* 7 (2011) 295–303.

85. First Coast Service Options (FCSO) Medical Policy. Surgical Management of Morbid Obesity, LCD #L14600, (02/21/06). Retired 02/01/09.
86. First Coast Service Options (FCSO) Medical Policy. Surgical Management of Morbid Obesity, LCD #L29317, (02/02/09). Last revised 02/19/15. Retired 09/30/15.
87. First Coast Service Options (FCSO) Medical Policy. Surgical Management of Morbid Obesity, LCD #L33411 (10/01/15).
88. Gagner M. Safety and efficacy of a side-to-side duodeno-ileal anastomosis for weight loss and type-2 diabetes: duodenal bipartition, a novel metabolic surgery procedure. *Ann Surg Innov Res.* 2015; 9: 6.
89. Guidance for Treatment of Adult Obesity, American Obesity Assoc., 1998.
90. Hayes Alert – Clinical Studies. Adjustable Gastric Banding Study Raises New Issues for Patient Selection. Vol IX, Number 5 (05/06).
91. Hayes Alert – Clinical Studies. Long-Term Health Outcomes 10 Years After Bariatric Surgery. Vol. VIII, Number 1 (01/05).
92. Hayes Alert – Clinical Studies. Study Finds Laparoscopic Gastric Bypass Better than Banding for Super-Obese Patients. Vol IX, Number 8 (08/06).
93. Hayes Brief – Bariatric Surgery for Pediatric Morbid Obesity, (01/19/06, revised 02/22/06).
94. Hayes Brief – Laparoscopic Mini-Gastric Bypass for Morbid Obesity (08/28/06).
95. Hayes Medical Technology Directory – Biliopancreatic Diversion with Duodenal Switch for Treatment of Obesity, (10/26/03).
96. Hayes Medical Technology Directory – Health Outcomes After Bariatric Surgery, (01/07/04).
97. Hayes Medical Technology Directory – Laparoscopic Bariatric Surgery – (11/03; Update report 12/24/06).
98. Hayes Medical Technology Directory – Laparoscopic Bariatric Surgery: Roux-en-Y Gastric Bypass, Vertical Banded Gastroplasty and Adjustable Gastric Banding. (06/07/07).
99. Hayes Medical Technology Directory – Obesity Management, Surgical Approaches. (10/99; updated 01/11/07).
100. Hayes Medical Technology Directory – Open and Laparoscopic Biliopancreatic Diversion. (06/07/07).
101. Hayes Medical Technology Directory – Open Malabsorptive Bariatric Surgery: Roux-en-Y. (06/07/07).
102. Hayes Medical Technology Directory – Open restrictive Bariatric Surgery: Gastroplasty and Gastric Banding. (06/07/07).
103. Hayes Medical Technology Directory – Pediatric Bariatric Surgery for Morbid Obesity. (06/07/07).
104. Hayes News Service – Clinical Study. Safety and Effectiveness of Laparoscopic Adjustable Banding. (10/17/08).
105. Hayes News Service Clinical Study – Bariatric Surgery Associated with long-term Weight Loss and Decreased Mortality. (09/04/07).
106. Hayes Search and Summery. Endoscopic Revision of Failed Bariatric Surgery. (11/21/08).
107. Helmiö M, Victorzon M, Ovaska J, Leivonen M, Juuti A, Jaser N, Peromaa P, Tolonen P, Hurme S, Salminen P. SLEEVEPASS: A randomized prospective multicenter study comparing laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: preliminary results. *Surgical endoscopy* 26, no. 9 (2012): 2521-2526.

108. Ikramuddin S, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. *Lancet Diabetes Endocrinol*. 2015 Jun;3(6):413-22.
109. Ikramuddin S, et al. Roux-en-Y Gastric Bypass vs Intensive Medical Management for the Control of Type 2 Diabetes, Hypertension, and Hyperlipidemia The Diabetes Surgery Study Randomized Clinical Trial. *JAMA*, June 5, 2013—Vol 309, No. 21.
110. International Diabetes Federation (IDF). Bariatric Surgical and Procedural Interventions in the Treatment of Obese Patients with Type 2 Diabetes. A position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Accessed 09/27/13 at: <http://www.idf.org/webdata/docs/IDF-Position-Statement-Bariatric-Surgery.pdf>.
111. InterQual Care Planning Criteria: General Surgery; Weight Loss Surgery GS-23, (2003).
112. InterQual Care Planning: Procedure Criteria; Bariatric Surgery, (2008).
113. InterQual Care Planning®: Procedures Adult, Bariatric Surgery (2009).
114. InterQual Care Planning®: Procedures Adult, Bariatric Surgery (2010).
115. InterQual® Care Planning 2012. Procedures Adult: Bariatric Surgery.
116. InterQual® Care Planning 2013. Procedures Adult: Bariatric Surgery.
117. InterQual® Care Planning 2014. Procedures Adult: Bariatric Surgery.
118. Jantz EJ et al. Number of weight loss attempts and maximum weight loss before Roux-en-Y laparoscopic gastric bypass surgery are not predictive of postoperative weight loss. *Surgery for Obesity and Related Diseases* 5 (2009) 208–211.
119. Jay M et al. Physicians' attitudes about obesity and their associations with competency and specialty: A cross-sectional study. *BioMed Central (BMC) Health Services Research* 2009, 9:106.
120. Ji Y, Wang Y, Zhu J, Shen D. A systematic review of gastric plication for the treatment of obesity. *Surg Obes Relat Dis*. 2013 Dec 12. pii: S1550-7289(13)00396-1.
121. Johnson WH, Fernandez AZ, Farrell TM, MacDonald KG, Grant JP, McMahon RL, Pryor AD, Wolfe LG, DeMaria EJ. Surgical revision of loop ("mini") gastric bypass procedure: multicenter review of complications and conversions to Roux-en-Y gastric bypass. *Surg Obes Relat Dis*. 2007 Jan-Feb;3(1):37-41.
122. Karcz WK, Kuesters S, Marjanovic G, Grueneberger JM. Duodeno-enteral omega switches - more physiological techniques in metabolic surgery. *Wideochir Inne Tech Malo Inwazyjne*. 2013 Dec;8(4):273-9.
123. Kim Z, Hur KY. Laparoscopic mini-gastric bypass for type 2 diabetes: the preliminary report. *World J Surg*. 2011 Mar;35(3):631-6.
124. Klein S et al. Economic Impact of the Clinical Benefits of Bariatric Surgery in Diabetes Patients With BMI ≥ 35 kg/m². *Obesity* (2011) 19, 581–587.
125. Kourkoulos M, Giorgakis E, Kokkinos C, Mavromatis T, Griniatsos J, Nikiteas N, Tsigris C. Laparoscopic gastric plication for the treatment of morbid obesity: a review. *Minim Invasive Surg*. 2012;2012:696348.
126. Kumar N. Endoscopic therapy for weight loss: Gastroplasty, duodenal sleeves, intragastric balloons, and aspiration. *World J Gastrointest Endosc*. 2015 Jul 25;7(9):847-59.
127. Laferrière B, Teixeira J, McGinty J, et al. The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 7 2479-2485. Effect of Weight Loss by Gastric Bypass Surgery Versus Hypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 Diabetes. Copyright © 2008 by The Endocrine Society.

128. Lee WJ, et al. Laparoscopic Roux-en-Y Versus Mini-Gastric Bypass for the Treatment of Morbid Obesity: A Prospective Randomized Controlled Clinical Trial. *Annals of Surgery* Volume 242, Number 1, July 2005.
129. Lee WJ, et al. Gastric Bypass vs Sleeve Gastrectomy for Type 2 Diabetes Mellitus: A Randomized Controlled Trial. *Arch Surg/Vol* 146 (No. 2) February 2011.
130. Lee WJ, Lee YC, Ser KH, Chen SC, Chen JC, Su YH. Revisional surgery for laparoscopic minigastric bypass. *Surg Obes Relat Dis*. 2011 Jul-Aug;7(4):486-91.
131. Lee WJ, Ser KH, Lee YC, Tsou JJ, Chen SC, Chen JC. Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. *Obes Surg*. 2012 Dec;22(12):1827-34.
132. Mahawar KK, Carr WR, Balupuri S, Small PK. Controversy surrounding 'mini' gastric bypass. *Obes Surg*. 2014 Feb;24(2):324-33.
133. Mahawar KK, Jennings N, Brown J, Gupta A, Balupuri S, Small PK. "Mini" gastric bypass: systematic review of a controversial procedure. *Obes Surg*. 2013 Nov;23(11):1890-8.
134. Mans E, et al. Sleeve gastrectomy effects on hunger, satiation, and gastrointestinal hormone and motility responses after a liquid meal test. *Am J Clin Nutr*. 2015 Sep;102(3):540-7.
135. Marchesini JB, Nicareta JR. Comparative study of five different surgical techniques for the treatment of morbid obesity using BAROS. *Arq Bras Cir Dig*. 2014;27 Suppl 1:17-20.
136. Mechanick JL, et al. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient—2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. *Obesity | VOLUME 21 | NUMBER S1 | MARCH 2013*.
137. Miller K, Pump A, Hell E. Vertical banded gastroplasty versus adjustable gastric banding: prospective long-term follow-up study. *Surg Obes Relat Dis* 2007; 3(1):84-90.
138. Milone M, Di Minno MN, Leongito M, Maietta P, Bianco P, Taffuri C, Gaudio D, Lupoli R, Savastano S, Milone F, Musella M. Bariatric surgery and diabetes remission: sleeve gastrectomy or mini-gastric bypass? *World J Gastroenterol*. 2013 Oct 21;19(39):6590-7.
139. Musella M, Susa A, Greco F, De Luca M, Manno E, Di Stefano C, Milone M, Bonfanti R, Segato G, Antonino A, Piazza L. The laparoscopic mini-gastric bypass: the Italian experience: outcomes from 974 consecutive cases in a multicenter review. *Surg Endosc*. 2014 Jan;28(1):156-63.
140. National Institutes of Health Consensus Development Conference on Gastrointestinal Surgery for Severe Obesity Statement (March 25-27, 1991).
141. National Institutes of Health, National Heart, Lung and Blood Institute, Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. *Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Executive Summary*. Bethesda, MD: National Institutes of Health; September 1998 (Accessed through website on 03/26/09).
142. National Institutes of Health, National Heart, Lung and Blood Institute, Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. *Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Executive Summary*. Bethesda, MD: National Institutes of Health; (09/98; accessed 04/18/07).
143. Norén E, Forssell H. Aspiration therapy for obesity; a safe and effective treatment. *BMC Obes*. 2016 Dec 28;3:56.
144. Noun R, Skaff J, Riachi E, Daher R, Antoun NA, Nasr M. One thousand consecutive mini-gastric bypass: short- and long-term outcome. *Obes Surg*. 2012 May;22(5):697-703.

145. Novak K. Bariatric Surgery: More than Expected. American Gastroenterological Association Journal. 09/08/11. Accessed at <http://agajournals.wordpress.com/tag/effects-of-bariatric-surgery/>.
146. Ochner CN et al. Pre-bariatric surgery weight loss requirements and the effect of preoperative weight loss on postoperative outcome. International Journal of Obesity (2012) 1–8.
147. Overcash WT. Natural orifice surgery (NOS) using StomaphyX for repair of gastric leaks after bariatric revisions. Obes Surg. 2008 Jul; 18(7): 882-5. Epub 2008 Apr 26.
148. Pattanshetti S, Tai CM, Yen YC, Lin HY, Chi SC, Huang CK. Laparoscopic adjustable gastric banded plication: evolution of procedure and 2-year results. Obes Surg. 2013 Nov;23(11):1934-8.
149. Peraglie C. Laparoscopic mini-gastric bypass (LMGB) in the super-super obese: outcomes in 16 patients. Obes Surg. 2008 Sep;18(9):1126-9.
150. Piazza L, Ferrara F, Leanza S, Coco D, Sarv  S, Bellia A, Di Stefano C, Basile F, Biondi A. Laparoscopic mini-gastric bypass: short-term single-institute experience. Updates Surg. 2011 Dec;63(4):239-42.
151. Poirier P, et al. Bariatric Surgery and Cardiovascular Risk Factors: A Scientific Statement From the American Heart Association. Circulation. 2011;123:1683-1701.
152. Pontiroli AE, Laneri M, Veronelli A, Frig  F, Micheletto G, Folli F, Adami G, Scopinaro N. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc Diabetol. 2009 Jul 20; 8:37.
153. Position Papers/Statements published on: 04/09 by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). SAGES Position Statement on Endolumenal Therapies for Gastrointestinal Diseases – Therapies for Obesity. (Accessed 08/19/10).
154. Rao WS, Shan CX, Zhang W, Jiang DZ, Qiu M. A Meta-Analysis of Short-Term Outcomes of Patients with Type 2 Diabetes Mellitus and BMI ≤ 35 kg/m² Undergoing Roux-en-Y Gastric Bypass. World Journal of Surgery August 2014.
155. Rutledge MD, Robert. "The Mini-Gastric Bypass: Experience with the First 1,274 Cases"; Obesity Surgery 2001; 11:276-280.
156. Ryou M, Thompson CC. Current Status of Endolumenal Bariatric Procedures for Primary and Revision Indications. Gastrointest Endosc Clin N Am. Apr 2011; 21(2): 315–333.
157. Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. N Engl J Med 2012;366:1567-76.
158. Schauer PR, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014 May 22;370(21):2002-13.
159. Sjostrom L et al. Bariatric Surgery and Long-term Cardiovascular Events. JAMA. 2012;307(1):56-65.
160. Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), with input from the Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery (ASMBS). Guidelines for Clinical Application of Laparoscopic Bariatric Surgery. March 2008. Accessed at <http://www.sages.org/publications/guidelines/guidelines-for-clinical-application-of-laparoscopic-bariatric-surgery/> on 11/13/15.
161. St. Anthony's ICD-9-CM Code Book (current edition).
162. Sudan R, Nguyen NT, Hutter MM, Brethauer SA, Ponce J, Morton JM. Morbidity, Mortality, and Weight Loss Outcomes After Reoperative Bariatric Surgery in the USA. J Gastrointest Surg. 2014 Sep 4.

163. Sullivan S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. *Gastroenterology*. 2013 Dec;145(6):1245-52.e1-5.
164. Sun Z, et al. Surgical treatment of medically refractory gastroparesis in the morbidly obese. *Surg Endosc*. 2015 Sep;29(9):2683-9.
165. Talebpour M, Motamedi SMK, Talebpour A, Vahidi H. Twelve year experience of laparoscopic gastric plication in morbid obesity: development of the technique and patient outcomes. *Ann Surg Innov Res*. 2012; 6: 7.
166. Tarnoff, T., Rodriguez, L., Escolona, A., Ramos, A., Neto, M., Alamo, M., Reyes, E., Pimentel, F., Ibanez, L. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. *Surg Endosc* (2009) 23:650-656.
167. The American Society for Metabolic and Bariatric Surgery Emerging Technologies and Clinical Issues Committees of the ASMBS. Approved by the ASMBS Executive Council January 2009. Emerging Endosurgical Interventions for Treatment of Obesity Position Statement and Standard of Care. (Accessed 08/19/10).
168. Tremaroli V, Karlsson F, Werling M, Ståhlman M, Kovatcheva-Datchary P, Olbers T, Fändriks L, le Roux CW, Nielsen J, Bäckhed F. Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. *Cell Metab*. 2015 Aug 4;22(2):228-38.
169. U.S. Food and Administration (FDA) Talk Paper, FDA Approves Implanted Stomach Band To Treat Severe Obesity, T01-26, 06/05/01.
170. U.S. Food and Drug Administration (FDA) LAP-BAND Adjustable Gastric banding System approval (Accessed 04/17/07).
171. Updated Position Statement on Sleeve Gastrectomy as a Bariatric Procedure Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery American Society for Metabolic and Bariatric Surgery, Gainesville, Florida. Received November 8, 2009; accepted November 9, 2009. (Accessed 08/19/10).
172. U.S. Preventive Services Task Force (USPSTF). Screening for and Management of Obesity in Adults. June 2012.
173. Vilallonga R, Fort JM, Caubet E, Gonzalez O, Balibrea JM, Ciudin A, Armengol M. Robotically Assisted Single Anastomosis Duodenoileal Bypass after Previous Sleeve Gastrectomy Implementing High Valuable Technology for Complex Procedures. *J Obes*. 2015;2015:586419.
174. Virk CS, Leitman IM, Goodman ER. Endoscopic gastric pouch plication - a novel endoluminal incision free approach to revisional bariatric surgery. *J Surg Case Rep*. 2010 Apr 1;2010(2):1.
175. Wadden TA et al. A Two-Year Randomized Trial of Obesity Treatment in Primary Care Practice. *N Engl J Med* 2011.
176. Werling M, Fändriks L, Björklund P, Maleckas A, Brandberg J, Lönroth H, le Roux CW, Olbers T. Long-term results of a randomized clinical trial comparing Roux-en-Y gastric bypass with vertical banded gastroplasty. *Br J Surg*. 2013 Jan;100(2):222-30.
177. Whitlock KA, et al. Early Outcomes of Roux-en-Y Gastric Bypass in a Publically Funded Obesity Program. *ISRN Obesity* Volume 2013, Article ID 296597. Hindawi Publishing Corporation.
178. Wu CC, Lee WJ, Ser KH, Chen JC, Tsou JJ, Chen SC, Kuan WS. Gastric cancer after mini-gastric bypass surgery: a case report and literature review. *Asian J Endosc Surg*. 2013 Nov;6(4):303-6.
179. Yip S, Plank LD, Murphy R. Gastric Bypass and Sleeve Gastrectomy for Type 2 Diabetes: A Systematic Review and Meta-analysis of Outcomes. *Obes Surg*. 2013 Aug 17.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy & Coverage Committee on 08/24/17.

GUIDELINE UPDATE INFORMATION:

10/15/99	Medical Coverage Guideline developed.
09/15/01	Various revisions.
01/01/02	Coding changes.
10/15/02	Annual review. Added Roux-enY anastomosis or vertical-banded as covered services. Added biliopancreatic bypass with duodenal switch and very long limb gastric bypass procedure (e.g., greater than 100 cm) as non-covered services.
05/15/03	Revised to clarify coding of the various procedures; criteria revised and is consistent with Inter-Qual criteria.
09/15/03	Coverage criteria for psychological testing/counseling revised.
10/15/03	Reversed investigational status for CPT code 43847 and provided coverage criteria for long-limb Roux-en-Y procedures up to 150 cm.
01/01/04	Annual HCPCS coding update.
04/01/04	2nd Quarter HCPCS coding update; added S2082 and S2083.
07/15/04	Scheduled review; no changes.
01/01/05	HCPCS coding update. Added 43644, 43645, 43845, S2082, and S2083. Revised descriptor for 43846, and deleted S2085.
05/15/05	Unscheduled review of the non-covered statement for laparoscopic adjustable gastric banding (Lap-Band); coverage statement unchanged.
01/01/06	Annual HCPCS coding update (added 43770 – 43774; deleted S2082).
04/15/06	Scheduled review; removed investigational statement for laparoscopic adjustable gastric banding and biliopancreatic diversion with duodenal switch; updated coding, index terms, and references.
05/15/06	Scheduled review; removed investigational statement for laparoscopic adjustable gastric banding and biliopancreatic diversion with duodenal switch; updated coding, index terms, and references; added age limitation of 18 years and older.
05/15/07	Scheduled annual review; reformatted guideline; modified coverage criteria regarding non-surgical weight loss programs; added description information and investigational statement regarding sleeve gastrectomy; updated references.
01/01/08	Annual HCPCS coding update: descriptor revisions for codes 43770 – 43774. Revised verbiage regarding adjustable gastric banding.
05/15/08	Scheduled annual review. Add investigational statement for endoscopic procedures. Update references.
05/15/09	Scheduled review; add CPT language for postoperative adjustment of gastric band to reimbursement section; updated position statement and description for long limb Roux-en Y greater than 150 cm; add presence of comorbidities to position statement; revise

	investigational statement to include transoral surgical procedures.
01/01/10	Annual HCPCS coding update: added CPT code 43775.
06/15/10	Annual review; no change in position statement. References updated.
10/01/10	4th Quarter HCPCS coding update consisting of adding ICD-9 diagnosis codes V85.41, V85.42, V85.43, V85.44 and V85.45.
11/15/10	Revision; position statement revised to include coverage criteria for Long-limb Gastric Bypass and Sleeve Gastrectomy; Medicare Advantage exception added; related ICD-10 codes added; Certificate of Medical Necessity added; references updated; guideline reformatted.
06/15/11	Annual review; no change in position statements. Updated Medicare Advantage program exception (delete CPT code 43775). Updated references.
09/15/11	Revision; formatting changes.
04/01/12	Revision; updated ICD10 coding with new and revised codes.
08/01/12	Scheduled review. Revised description section. Revised position statement; added coverage criteria for Biliopancreatic Bypass (i.e., the Scopinaro procedure) and designated Long-Limb Roux-en-Y (LLRY) as E/I. Removed time requirements for duration of BMI and attempts at non-surgical weight loss. Revised Medicare Advantage program exception. Updated references and reformatted guideline.
11/15/13	Scheduled review. Revised MCG title and description section. Revised position statement (added criteria for adolescents, designated vertical banded gastroplasty as E/I). Revised ICD9/ICD10 coding sections, program exception section (Medicare Advantage), related guidelines, and definitions. Updated references.
05/15/14	Unscheduled review (mini-gastric bypass); position statement maintained. Revised CPT coding section and updated references.
01/01/15	Scheduled review. Revised description section, position statement and program exceptions. Updated references.
12/15/15	Scheduled review. Revised position statement (added coverage for vertical banded gastroplasty). Updated Program Exceptions section and references.
04/15/16	Revision; added coverage statement (E/I) for anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S).
10/01/16	Revision: Billing/Coding Information section updated.
06/15/17	Scheduled review. Revised description section. Added coverage statement (E/I) for aspiration therapy. Updated references.
09/15/17	Revision: added coverage statement for bariatric surgery performed as primary treatment for conditions other than morbid obesity. Added code 43633. Updated references.
07/19/18	Revision to Position Statement.